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Volume 56, Number 6 Abstracts 1815Atlantic Intersocietal Conference (TASC) II guidelines. The aim of this study
was to determine the proportion of patients with chronic critical limb ischemia
(CLI) who failed to adhere to current guidelines of medical therapy and to
quantify the effect of suboptimal medical management on amputation-free
survival (AFS).
Methods: The patient cohort was identified from a prospectively
maintained database of consecutive patients presenting with CLI to the
vascular surgery service at one hospital. The primary outcome variable was
AFS. The effects of baseline demographics, comorbid medical conditions,
ambulatory status, optimal medical management, and Rutherford classifica-
tion were assessed. Optimal medical management was defined as adherence
to TASC II recommendations for the management of atherosclerotic risk
factors. Significant univariate predictors (P .10) of AFS were entered into
a multivariate Cox proportional hazards model.
Results: From August 1, 2010, through January 1, 2012, 98 patients
(mean [standard deviation] age, 59.9 10.1 years; 58 men and 40 women)
were evaluated with rest pain (n  38) or tissue loss (n  60). The mean
follow-up for the cohort was 333.3  196.1 days. Optimal medical man-
agement was identified in 32% of patients at initial presentation, including
compliance rates of 63% for statin use, 71% on antiplatelet therapy, 51% for
angiotensin-converting enzyme inhibitor use, and 49% for -blocker use.
Significant univariate predictors of major amputation or death included
nonambulatory status (hazard ratio [HR] 2.17; 95% confidence interval
[CI], 1.68-2.81; P  .01), un-revascularized patients (HR, 2.77; 95% CI,
1.32-5.85; P  .01), a history of tobacco abuse (HR, 1.49; 95% CI,
0.57-3.86; P  .09), a history of end-stage-renal disease (HR, 7.97; 95%
CI, 3.10-20.52; P .01), suboptimal medical management (HR, 4.25; 95%
CI, 1.28-14.07; P  .02), and an absence of antiplatelet agents (HR, 1.94;
95% CI, 0.92-4.11; P  .08). Independent predictors of major amputation
or death included initial nonambulatory status (HR, 2.43; 95% CI, 1.03-
2.05; P .01), un-revascularized status (HR, 2.43; 95% CI, 1.76-3.34; P
.01), and suboptimal medical management at presentation (HR, 8.54; 95%
CI, 2.05-35.65; P  .01).
Conclusions: Despite guidelines advocating the optimization of ath-
erosclerotic risk factors in peripheral arterial disease, less than one-third of
patients with CLI present with their risk factors appropriately managed.
Patients who are suboptimally medically managed have greater than a
fourfold risk of major amputation or death, or both. Of the risk factors
affecting amputation-free survival, medical therapy optimization is the vari-
able that can be most significantly improved by vascular surgeons and the
medical community. Population-based efforts to improve outcomes in CLI
require attention to improving the medical management.
Carotid-Subclavian Bypass and Subclavian-Carotid Transposition in
the TEVAR Era
Arin L. Madenci,1 C. Keith Ozaki,2 Michael Belkin,2 James T. McPhee2. 1Uni-
versity of Michigan Medical School, Ann Arbor, Mich; 2Brigham and Women’s
Hospital, Boston,Mass
Introduction: Beyond traditional indications, subclavian revascular-
ization is increasingly performed to allow for aortic arch debranching in the
setting of thoracic endovascular aortic repair (TEVAR). Endovascular ap-
proaches have also emerged as a therapeutic option for subclavian artery
disease, perhaps altering the patient population undergoing open proce-
dures. We leveraged prospectively collected National Surgical Quality Im-
provement Program (NSQIP) data to delineate evolving stroke and mortal-
ity rates after carotid-subclavian bypass (CSB) and subclavian-carotid
transposition (SCT) in this dynamic context.
Methods: The American College of Surgeons NSQIP database (2005-
2010) was used to examine adult patients who underwent CSB or SCT.
Patients admitted for emergency procedures were excluded. Factors associ-
ated with the primary outcome (30-day postoperative stroke or death) were
defined using univariable and multivariable analyses.
Results: Of 877 patients who met inclusion and exclusion criteria, 738
underwent CSB, 139 underwent SCT, and 88 (10.0%) also underwent TE-
VAR. CSB comprised 41% of subclavian revascularizations associated with
TEVAR and 89% of isolated subclavian revascularizations. The CSB and SCT
group had similar baseline age (65.0 vs 63.3 years, P  .67), race (Caucasian,
83.8% vs 79.4%, P .21), and prevalence of comorbid conditions. There were
a greater proportion of TEVARs performed in the SCT group (37.4% vs 4.9%,
P .01). The groups were otherwise similar in demographic characteristics and
prevalence of comorbid conditions. Overall stroke, mortality, and combined
cerebrovascular accident (CVA)/death (D) rateswere 3.5% (n31), 3.3% (n
29), and 5.8% (n  51), respectively. Surgical approach did not affect the
CVA/D rate (odds ratio [OR], 1.51; 95% confidence interval [CI], 0.71-3.19;
P .28); however, increasing age (adjustedOR, 1.06; 95%CI, 1.03-1.10; P
.01), congestive heart failure (OR, 3.49; 95% CI, 1.04-11.64; P  .04), and
American Society of Anesthesiologists class3 (OR, 2.06; 95% CI, 1.11-3.83;
P  .02) were significantly associated with CVA/D in the overall group. The
CVA/D rate was 10.2% (n  9) for revascularization in conjunction with
TEVAR and 5.3% (n  42) for isolated reconstruction (P  .06). Without
excluding emergency cases, the TEVAR cohort’s CVA/D rate was 14.7%. For
patientsundergoingTEVAR,no factorswere significantly associatedwithCVA/D,
m
tncluding surgical approach (SCTvsCSB;OR,0.52; 95%CI, 0.13, 2.08;P .35).
or patients undergoing isolated revascularization, increasing age (OR, 1.06; 95%
I, 1.03-1.10;P .01) andnonindependent functional status (OR,3.49; 95%CI,
.41-8.68; P .01) were significantly associated with CVA/D.
Conclusions: Despite improvements in surgical, anesthetic, and
ritical care technology, open cervical reconstruction of the subclavian
rtery for occlusive disease carries a persistent combined CVA/D rate
5% in this contemporary work. With TEVAR, this rate is as high as
0.2%. There was no significant difference in CVA/D by surgical ap-
roach after adjustment for other factors. CVA/D continues to compli-
ate contemporary CSB and SCT, especially among elderly and noninde-
endent patient subsets.
able. Outcome, stratified by TEVAR and surgical approach
ariable No. CVA/D Death CVA
No. (%) No. (%) No. (%)
ll patients 877 51 (5.8) 29 (3.3) 31 (3.5)
EVAR
Overall 88 9 (10.2) 6 (6.8) 5 (5.7)
CSB 36 5 (13.9) 3 (8.3) 3 (8.3)
SCT 52 4 (7.7) 3 (5.8) 2 (3.9)
on-TEVAR
Overall 789 42 (5.3) 23 (2.9) 26 (3.3)
CSB 702 36 (5.1) 20 (2.9) 22 (3.1)
SCT 87 6 (6.9) 3 (3.5) 4 (4.6)
mproved Procedural, Hemodynamic, and Late Clinical Outcomes
sing Intravascular Ultrasound Anatomic Guidance During Carotid
rtery Stent-Angioplasty
egan I. Carroll, Patrick McNair, Martin R. Back, Neil Moudgill, Murray
. Shames, Karl A. Illig, Brad L. Johnson, Paul A. Armstrong. University of
outh Florida, Tampa, Fla
Introduction: This study evaluates carotid artery stenting (CAS) with
nd without intravascular ultrasound (IVUS) interrogation assessing the
egion of stent deployment and angioplasty.
Methods: A retrospective review of a carotid stent registry from 2003
o 2012 identified 412 CAS procedures (399 patients) to treat de novo
therosclerosis or recurrent stenosis of the carotid bulb and internal carotid
rtery. Imaging with IVUS was performed before and after stent-angio-
lasty. Residual stent stenosis on angiography or IVUS was treated with
dditional percutaneous transluminal angioplasty (PTA). Surveillance du-
lex ultrasound imaging was performed at 30 days, followed by 6-month
ntervals. Outcome measures included procedure time, final balloon diam-
ter for PTA, contrast volume, hemodynamic parameters on duplex, cardiac
vents, neurologic outcome, and mortality.
Results: CAS was performed using digital C-arm angiography alone
AA) in 167 or in conjunction with IVUS (AI) in 241; 314 patients (77%)
ere asymptomatic. Using AA or AI, accurate single carotid stent deploy-
ent was achieved. Mean procedure times were similar between AA and AI
roups (63.0 vs 63.4 min, P  .87). Compared with AA, AI altered
rocedural conduct by using lower contrast volumes (mean 50 mL; range
-120 mL) compared with AA (mean, 90 mL; range, 40-170 mL) due to
ewer angiogram runs for stent sizing and verification of adequate stent
eployment. AI directed use of larger-diameter balloons, ranging in size
rom 5.5 to 7 mm (median 6 mm), for final stent PTA based on assessment
f normal luminal diameter, whereas AA balloons were 4.5 to 6 mm
median, 5 mm; P  .0001). AI also detected more residual stent abnor-
alities (n 24 [10%]) vs CAS using AA (n 3 [2%], P .002). The early
30-day) duplex scan showed 24 of 27 stents (89%) receiving adjunctive
TA for residual stent stenosis demonstrated 50% DR. Early neurologic
vent rates were low, and there was no different between groups (AA 1.2% vs
I 1.2%). Duplex at 30-days and last surveillance interval is recorded in the
able. Mean follow-up was 54 months (range, 6-120 months). Duplex at
0-days showed DR 50% to 75% was more likely in the AA group (P .02).
t the last duplex, DR50% were recorded for 26 AA (16%) and 9 AI CAS
4%; P  .0001). Six CAS sites (5 AA, 1 AI, P  .0001) developed 75%
symptomatic restenosis and underwent secondary percutaneous interven-
ion with PTA, with one AA stent later developing an asymptomatic throm-
osis. Each group had one late neurologic event, one stroke (AA), and one
ransient ischemic attack (AI; 0.6%, 0.4% respectively). One early cardiac
eath was recorded in an AI patient.
Conclusions: IVUS guidance allows operators to accurately define
isease distribution, vessel size, and target stent landing zones without
dding independent risk or increasing procedural time. IVUS affords a
easure of quality control that directs optimal stent and balloon selec-
ion. Adjunctive use of IVUS can improve early and late carotid stent
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December 20121816 Abstractshemodynamics, which may enhance outcomes and reduce secondary
interventions for recurrent stenosis.
Table. Hemodynamic parameters
Variable 30-day duplex scan Most recent duplex scan
50%
DR
50-75%
DR
75%
DR
50%
DR
50-75%
DR
75%
DR
Angio alone, No.
(%)
152 15 (9) 0 141 21 (13) 5 (3)
Mean PSV (cm/s) 98  46 198  47 . . . 106  38 204  51 422  45
Angio  IVUS,
No. (%)
233 8 (3) 0 232 8 (3) 1 (0.4)
Mean PSV (cm/s) 84  50 182  31 . . . . 82  40 186  28 347
Stress Tests Are Overutilized in the Preoperative Evaluation of Endo-
vascular Aneurysm Repair
Siddharth Patel, Richard Gilmore, Yazan Duwayri, Ravi Rajani, James
Reeves, Luke Brewster, Thomas Dodson, Ravi Veeraswamy. Emory Uni-
versity School of Medicine, Atlanta, Ga
Introduction: The ideal approach for cardiac risk stratification in patients
undergoing elective endovascular aortic aneurysm repair (EVAR) remains un-
resolved. Multiple algorithms are used to evaluate patients, with significant
variability amongst institutions, and cardiac stress testing remains a widely used
modality. Recent American College of Cardiology/American Heart Associa-
tion guidelines suggest clinical risk factors can identify patients at highest risk for
adverse events. We compared the clinical efficacy and cost-savings of risk factor
assessment using the revised cardiac risk index (RCRI) vs cardiac stress testing in
predicting perioperative cardiac complications after EVAR.
Methods: A single-center retrospective study was conducted to identify
patients undergoingEVARbetween 2009 and 2011.Of 248 patients whowere
identified, 42 were excluded due to emergent repair, and 206 patients were
included in the analysis. The preoperative assessment was identified and a cost
analysis was performed based on CMS reimbursement rates for our geographic
area. The RCRI was calculated for each patient and used to stratify them
according to predicted risk for a perioperative cardiac event. The 30-day event
rates for death or symptomatic cardiac events were calculated.
Results: Complete records for preoperative evaluations were available
for 197 of the 206 patients. Of those, 168 (85%) underwent cardiac stress
testing, of which 26 patients (13%) were positive, resulting in further testing.
Twenty patients with a positive stress test underwent cardiac catheterization,
three underwent percutaneous coronary intervention (PCI), and one under-
went coronary artery bypass grafting. There were no perioperative deaths.
Six patients (2.9%) had clinical symptoms prompting measurement of serum
troponin levels, which were elevated. In patients with a negative stress test,
five myocardial infarctions (MIs) occurred (3%) vs one MI in patients with a
positive stress test (3.8%; P  .86). When stratified by the RCRI, patients
with fewer than three risk factors had anMI rate of 2.5% vs 16.7% in patients
with three or more factors (P .04). Including the resultant procedures, the
per-patient cost for routine preoperative stress testing was $3500.
Conclusions: Routine preoperative cardiac stress testing for patients
undergoing elective endovascular aneurysm repair is unwarranted. It results
in additional invasive testing and therapy with a concomitant cost increase.
The RCRI is a reliable tool for risk stratification and guiding preoperative
workup in patients scheduled for elective EVAR. The RCRI should replace
qualitative physician determination of fitness for EVAR. This represents a
potential area for improved resource utilization strategies.
Table. Stress test and perioperative MI by risk score
RCRI risk score
Stress test, No. (%) MI, No. (%)
Yes No. Yes No.
3 163 (85) 28 (15) 5 (2.5) 195 (97.5)
3 5 (83) 1 (17) 1 (17) 5 (83)
Percutaneous Endovascular Aortic Aneurysm Repair (PEVAR): Re-
sults From the First Prospective, Multicenter Randomized Trial
Peter R. Nelson. University of Florida College of Medicine, Gainesville, Fla
Introduction: The first randomized controlled trial was designed and
conducted to assess the safety and effectiveness of totally percutaneous
endovascular aortic aneurysm repair (PEVAR) using a 21F endovascular
stent graft system and an 8F or 10F suture-mediated closure system. A
noninferiority trial design was chosen to compare percutaneous access to
standard open femoral exposure.Methods: Between 2010 and 2012, 20 United States institutions
participated in a prospective, U.S. Food and Drug Administration-approved
a
sandomized trial to evaluate the safety and effectiveness of percutaneous
emoral artery access and closure using a “preclose” technique in conjunc-
ion with EVAR. A total of 192 patients were enrolled, 41 in a nonrandom-
zed roll-in phase, and then 151 in the randomized phase where patients
ere allocated 2:1 to percutaneous closure (group C, n  101) or open
emoral exposure (group S, n  50). PEVAR procedures were performed
sing the 8F Perclose ProGlide (group C1, n  50) or the 10F Prostar XL
group C2, n  51) closure device. All EVAR procedures were performed
ith the 21F profile IntuiTrak System. Patients were screened using com-
uted tomography with 3-dimensional reconstruction and independent
hysician review for anatomic suitability and adequate femoral artery anat-
my for percutaneous access (eg, absence of anterior wall or circumferential
alcification, aneurysm, or extensive scarring). Primary treatment success
as defined as procedural technical success and absence of adverse systemic
nd access-related vascular events at 30 days. Secondary clinical utility and
rocedural outcomes, ankle-brachial index, blood laboratory analyses, and
uality of life were also evaluated with continuing follow-up to 6 months.
Results: Baseline characteristics were similar among all groups. EVAR
echnical success was 100%, 100%, and 98% in groups C1, C2, and S,
espectively. Primary treatment success at 1 month was 88% (C1), 78% (C2),
nd 78% (S) with a one-sided Blackwelder’s test of noninferiority yielding
 .0036 for C1 vs S and P  .1021 for C2 vs S. Secondary outcomes
rocedurally to within 1 month are shown in the Table. PEVAR (group C)
ompared favorably with respect to time to hemostasis, anesthesia time, total
rocedure time, analgesic use, ipsilateral groin pain, blood transfusion require-
ent, and quality of life metrics. Final 6-month follow-up is ongoing.
Conclusions: Among trained operators and patients with suitable femo-
al artery anatomy, a totally percutaneous approach to EVAR is safe, with
inimal access-related complications. The ProGlide suture-mediated device
pecifically performed noninferiorly to standard open femoral exposure. Train-
ng, experience, and careful application of the “preclose” technique is of para-
ount importance in ensuring successful, sustainable outcomes.
able.
utcome measure Group C1 Group C2 Group S
nesthesia time, minutes 181  65 152  54a 203  93
ime to hemostasis, minutes 9.8  17a 13  19a 23  23
otal procedure Time, minutes 101  43a 95  35a 136  71
stimated blood loss, mL 213  205 193  198 280  290
lood transfusion, % patients 4.0% 16% 14%
ime to ambulation, hours 17  7.2 16  9.1 19  16
ime to normal diet, hours 14  9.4 10  8.4 15  22
psilateral groin pain
pre-dischargeb
2.1  2.2 1.4  2.0a 2.6  2.4
nalgesics for groin pain
pre-discharge, % patients
18% 12%a 30%
ime to hospital discharge, days 1.3  0.7 1.4  0.9 1.8  2.4
psilateral groin pain at 1
monthb
0.4  0.9 0.1  0.5a 0.6  1.5
F-36 health-related quality of
life change at 1 month
9.4  26 8.3  29 1.6  24
psilateral ankle-brachial index
at 1 month
1.06  0.16 1.05  0.15 1.06  0.13
esults shown as mean  SD unless otherwise specified.
P.05 vs group S result.
Scale of 0 (no pain) to 10 (worst pain imaginable).
equential Catheterization Amid Progressive Endograft Deployment
or Fenestrated and Branched Endovascular Aortic Aneurysm Repair
regory A. Stanley, Carlos H. Timaran, M. Shadman Baig, J. Gregory
odrall, David E. Timaran, L. F. Gomez, R. James Valentine. University of
exas Southwestern, Dallas, Tex
Introduction: Fenestrated and branched endovascular aneurysm repair
FEVAR) is an alternative to open repair of complex aortic aneurysms in
igh-risk patients. Unfortunately, patients with unfavorable anatomy are fre-
uently denied FEVAR because of the risk of technical failure with loss of
isceral arteries. The purpose of this study was to assess technical success of
EVAR using a sequential catheterization amid progressive endograft deploy-
ent (SCAPED) technique, particularly in patients with unfavorable anatomy.
Methods: During a 12-month period, 39 high-risk patients (31 men
nd 8 women) underwent FEVAR using customized, physician-modified
enith endografts that were fenestrated or branched using the SCAPED
echnique. The visceral vessels were sequentially catheterized through the
enestrations via left brachial artery access in a cranial-to-caudal direction as
he endograft was progressively deployed. Each fenestration was deployed,
ligned, and catheterized separately while the distal endograft was con-
trained within the delivery sheath. Technical success was defined as com-
